1
|
Deng H, Leigh C, Yang Y, Jin Z, Sun G, Zhang L, Feng X, Moshos K, White B. Acyl Glucuronide of Oxidized Lenabasum (JBT‐101) as Human Major Metabolite: Identification, Large‐Scale Synthesis, and Activity Characterization. ChemistrySelect 2021. [DOI: 10.1002/slct.202103050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Hongfeng Deng
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Clifton Leigh
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Yun Yang
- WuXi AppTec (Tianjin) Co., Ltd Tianjin 300457 P. R. China
| | - Zhuang Jin
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Gang Sun
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Lipeng Zhang
- WuXi AppTec (Tianjin) Co., Ltd Tianjin 300457 P. R. China
| | - Xiao Feng
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Kristos Moshos
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| | - Barbara White
- Corbus Pharmaceuticals Inc. Norwood MA 02062 United States
| |
Collapse
|
2
|
Acyl glucuronide reactivity in perspective. Drug Discov Today 2020; 25:1639-1650. [PMID: 32681884 DOI: 10.1016/j.drudis.2020.07.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 06/22/2020] [Accepted: 07/08/2020] [Indexed: 12/12/2022]
Abstract
Acyl glucuronidation is a common metabolic fate for acidic drugs and their metabolites and, because these metabolites are reactive, they have been linked to adverse drug reactions (ADRs) and drug withdrawals. However, alternative routes of metabolism leading to reactive metabolites (e.g., oxidations and acyl-CoA thioesters) mean that unambiguous proof that acyl glucuronides are toxic is lacking. Here, we review the synthesis and reactivity of these metabolites, and describe the use of molecular modelling and in vitro and in vivo reactivity assessment of acyl glucuronide reactivity. Based on the emerging structure-dependent differences in reactivity and protein adduction methods for risk assessment for acyl glucuronide-forming acid drugs or drug candidates in drug discovery/development are suggested.
Collapse
|
3
|
Bradshaw PR, Richards SE, Wilson ID, Stachulski AV, Lindon JC, Athersuch TJ. Kinetic modelling of acyl glucuronide and glucoside reactivity and development of structure–property relationships. Org Biomol Chem 2020; 18:1389-1401. [DOI: 10.1039/c9ob02008j] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Detailed kinetic and transition structure modelling to rationalise the differences in reactivity observed between the acyl glucuronide and glucoside metabolites of a series of phenylacetic acid analogues.
Collapse
Affiliation(s)
- Peter R. Bradshaw
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Selena E. Richards
- Department of Chemistry
- Khalifa University of Science and Technology
- Abu Dhabi
- United Arab Emirates
| | - Ian D. Wilson
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Andrew V. Stachulski
- Department of Chemistry
- The Robert Robinson Laboratories
- University of Liverpool
- Liverpool L69 7ZD
- UK
| | - John C. Lindon
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| | - Toby J. Athersuch
- Department of Metabolism
- Digestion and Reproduction
- Faculty of Medicine
- Imperial College London
- London
| |
Collapse
|
4
|
Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs. Bioorg Med Chem Lett 2019; 29:1842-1848. [DOI: 10.1016/j.bmcl.2019.04.050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 04/16/2019] [Accepted: 04/30/2019] [Indexed: 01/21/2023]
|
5
|
Tiwari V, Singh AK, Chaudhary P, Seeberger PH, Kandasamy J. Synthesis of photolabile protecting group (PPG) protected uronic acid building blocks: applications in carbohydrate synthesis with the assistance of a continuous flow photoreactor. Org Chem Front 2019. [DOI: 10.1039/c9qo01010f] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Photolabile groups protected uronic acid building blocks were synthesized and used for carbohydrate synthesis with the help of a continuous flow photo-reactor.
Collapse
Affiliation(s)
- Varsha Tiwari
- Department of chemistry
- Indian Institute of Technology (BHU)
- Varanasi
- India
| | - Adesh Kumar Singh
- Department of chemistry
- Indian Institute of Technology (BHU)
- Varanasi
- India
| | - Priyanka Chaudhary
- Department of chemistry
- Indian Institute of Technology (BHU)
- Varanasi
- India
| | - Peter H. Seeberger
- Max-Planck-Institute of Colloids and Interfaces
- Department of Biomolecular Systems
- 14476 Potsdam
- Germany
| | | |
Collapse
|
6
|
Practical one-step glucuronidation via biotransformation. Bioorg Med Chem Lett 2018; 29:199-203. [PMID: 30551902 DOI: 10.1016/j.bmcl.2018.11.056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 11/21/2018] [Accepted: 11/28/2018] [Indexed: 12/22/2022]
Abstract
We herein report a practical one-step glucuronidation method by biotransformation using Streptomyces sp. SANK 60895. This novel direct method of biotransformation has been shown to be more practical and scalable for glucuronidation than previously reported chemical and enzymatic procedures given its simplicity, high β-selectivity, cost-effectiveness, and reproducibility. We applied the present method to the synthesis of acyl glucuronide and hydroxy-β-glucuronide of mycophenolic acid and compound 4, respectively. This method was also shown to be applicable to the N-glucuronidation of various compounds.
Collapse
|
7
|
Possiel C, Bäuerle A, Seibel J. A Chemoenzymatic Route to a Class of Sucrose Esters. European J Org Chem 2017. [DOI: 10.1002/ejoc.201701313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Christian Possiel
- Institut für Organische Chemie; Julius-Maximilians Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Alexandra Bäuerle
- Institut für Organische Chemie; Julius-Maximilians Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Jürgen Seibel
- Institut für Organische Chemie; Julius-Maximilians Universität Würzburg; Am Hubland 97074 Würzburg Germany
| |
Collapse
|
8
|
Kanamori T, Yamamuro T, Kuwayama K, Tsujikawa K, Iwata YT, Inoue H. Synthesis and Analysis of Glucuronic Acid-Conjugated Metabolites of 4-Bromo-2,5-Dimethoxyphenethylamine. J Forensic Sci 2016; 62:488-492. [DOI: 10.1111/1556-4029.13266] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Revised: 05/12/2016] [Accepted: 05/22/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Tatsuyuki Kanamori
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| | - Tadashi Yamamuro
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| | - Kenji Kuwayama
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| | - Kenji Tsujikawa
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| | - Yuko T. Iwata
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| | - Hiroyuki Inoue
- National Research Institute of Police Science; 6-3-1, Kashiwanoha Kashiwa 277-0882 Japan
| |
Collapse
|
9
|
Yuan Y, Zheng J, Wang M, Li Y, Ruan J, Zhang H. Metabolic Activation of Rhein: Insights into the Potential Toxicity Induced by Rhein-Containing Herbs. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2016; 64:5742-5750. [PMID: 27362917 DOI: 10.1021/acs.jafc.6b01872] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Rhein is a major component of the many medicinal herbs such as rhubarb. Despite wide use, intoxication cases associated with rhein-containing herbs are often reported. The present work aimed to investigate if rhein was subject to metabolic activation leading to toxicity. Upon incubations with different species of liver microsomes, three monoglucuronides were identified, corresponding to two hydroxyl glucuronides and one acyl glucuronide via the carboxyl group, respectively. Further study revealed that rhein acyl glucuronide was chemically reactive, and showed cytotoxicity toward hepatocarcinoma cells. In addition, significant species differences in glucuronidation of rhein were observed between laboratory animals and humans. Reaction phenotyping experiments demonstrated that rhein acyl glucuronide was catalyzed predominantly by uridine 5'-diphospho-glucuronosyltransferase 1A1, 1A9, and 2B7. Taken together, the present study confirmed that rhein could be metabolically activated via the formation of acyl glucuronide, especially in human.
Collapse
Affiliation(s)
- Yuan Yuan
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| | - Jiyue Zheng
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| | - Meiyu Wang
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| | - Yuan Li
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| | - Jianqing Ruan
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| | - Hongjian Zhang
- College of Pharmaceutical Sciences, Soochow University , Suzhou, 215123, China
| |
Collapse
|
10
|
Nagao M, Suzuki M, Takano Y. The practical synthesis of β-acyl glucuronides by using allyl 2,3,4-tri-( O -allyloxycarbonyl)- d -glucuronate and 1-chloro- N , N ,2-trimethyl-1-propenylamine. Tetrahedron Lett 2016. [DOI: 10.1016/j.tetlet.2016.06.057] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Ikushiro S, Nishikawa M, Masuyama Y, Shouji T, Fujii M, Hamada M, Nakajima N, Finel M, Yasuda K, Kamakura M, Sakaki T. Biosynthesis of Drug Glucuronide Metabolites in the Budding Yeast Saccharomyces cerevisiae. Mol Pharm 2016; 13:2274-82. [DOI: 10.1021/acs.molpharmaceut.5b00954] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Shinichi Ikushiro
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Miyu Nishikawa
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
- Imizu
Institute, TOPU BIO RESEARCH Co., Ltd, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Yuuka Masuyama
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Tadashi Shouji
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Miharu Fujii
- Imizu
Institute, TOPU BIO RESEARCH Co., Ltd, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Masahiro Hamada
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Noriyuki Nakajima
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Moshe Finel
- Division
of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56, 00014 Helsinki, Finland
| | - Kaori Yasuda
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Masaki Kamakura
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| | - Toshiyuki Sakaki
- Department
of Biotechnology, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
- Imizu
Institute, TOPU BIO RESEARCH Co., Ltd, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
| |
Collapse
|
12
|
Latli B, Hrapchak M, Chevliakov M, Li G, Campbell S, Busacca CA, Senanayake CH. Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon-13 and carbon-14. J Labelled Comp Radiopharm 2015; 58:250-60. [PMID: 25964148 DOI: 10.1002/jlcr.3294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 03/10/2015] [Accepted: 04/01/2015] [Indexed: 01/09/2023]
Abstract
Deleobuvir, (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol-6-yl)prop-2-enoic acid (1), is a non-nucleoside, potent, and selective inhibitor of hepatitis C virus NS5B polymerase. Herein, we describe the detailed synthesis of this compound labeled with carbon-13 and carbon-14. The synthesis of its three major metabolites, namely, the reduced double bond metabolite (2) and the acyl glucuronide derivatives of (1) and (2), is also reported. Aniline-(13) C6 was the starting material to prepare butyl (E)-3-(3-methylamino-4-nitrophenyl-(13) C6 )acrylate [(13) C6 ]-(11) in six steps. This intermediate was then used to obtain [(13) C6 ]-(1) and [(13) C6 ]-(2) in five and four more steps, respectively. For the radioactive synthesis, potassium cyanide-(14) C was used to prepare 1-cylobutylaminoacid [(14) C]-(23) via Buchrer-Bergs reaction. The carbonyl chloride of this acid was then used to access both [(14) C]-(1) and [(14) C]-(2) in four steps. The acyl glucuronide derivatives [(13) C6 ]-(3), [(13) C6 ]-(4) and [(14) C]-(3) were synthesized in three steps from the acids [(13) C6 ]-(1), [(13) C6 ]-(2) and [(14) C]-(1) using known procedures.
Collapse
Affiliation(s)
- Bachir Latli
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Matt Hrapchak
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Maxim Chevliakov
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Guisheng Li
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Scot Campbell
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Carl A Busacca
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| | - Chris H Senanayake
- Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, 06877-0368, USA
| |
Collapse
|
13
|
d'Errico C, Jørgensen JO, Krogh KBRM, Spodsberg N, Madsen R, Monrad RN. Enzymatic degradation of lignin-carbohydrate complexes (LCCs): model studies using a fungal glucuronoyl esterase from Cerrena unicolor. Biotechnol Bioeng 2015; 112:914-22. [PMID: 25425346 DOI: 10.1002/bit.25508] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 11/14/2014] [Accepted: 11/17/2014] [Indexed: 11/09/2022]
Abstract
Lignin-carbohydrate complexes (LCCs) are believed to influence the recalcitrance of lignocellulosic plant material preventing optimal utilization of biomass in e.g. forestry, feed and biofuel applications. The recently emerged carbohydrate esterase (CE) 15 family of glucuronoyl esterases (GEs) has been proposed to degrade ester LCC bonds between glucuronic acids in xylans and lignin alcohols thereby potentially improving delignification of lignocellulosic biomass when applied in conjunction with other cellulases, hemicellulases and oxidoreductases. Herein, we report the synthesis of four new GE model substrates comprising α- and ɣ-arylalkyl esters representative of the lignin part of naturally occurring ester LCCs as well as the cloning and purification of a novel GE from Cerrena unicolor (CuGE). Together with a known GE from Schizophyllum commune (ScGE), CuGE was biochemically characterized by means of Michaelis-Menten kinetics with respect to substrate specificity using the synthesized compounds. For both enzymes, a strong preference for 4-O-methyl glucuronoyl esters rather than unsubstituted glucuronoyl esters was observed. Moreover, we found that α-arylalkyl esters of methyl α-D-glucuronic acid are more easily cleaved by GEs than their corresponding ɣ-arylalkyl esters. Furthermore, our results suggest a preference of CuGE for glucuronoyl esters of bulky alcohols supporting the suggested biological action of GEs on LCCs. The synthesis of relevant GE model substrates presented here may provide a valuable tool for the screening, selection and development of industrially relevant GEs for delignification of biomass.
Collapse
Affiliation(s)
- Clotilde d'Errico
- Department of Chemistry, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | | | | | | | | | | |
Collapse
|
14
|
Hammond TG, Meng X, Jenkins RE, Maggs JL, Castelazo AS, Regan SL, Bennett SNL, Earnshaw CJ, Aithal GP, Pande I, Kenna JG, Stachulski AV, Park BK, Williams DP. Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients. J Pharmacol Exp Ther 2014; 350:387-402. [PMID: 24902585 PMCID: PMC4109494 DOI: 10.1124/jpet.114.215079] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 05/29/2014] [Indexed: 12/21/2022] Open
Abstract
Covalent protein modifications by electrophilic acyl glucuronide (AG) metabolites are hypothetical causes of hypersensitivity reactions associated with certain carboxylate drugs. The complex rearrangements and reactivities of drug AG have been defined in great detail, and protein adducts of carboxylate drugs, such as diclofenac, have been found in liver and plasma of experimental animals and humans. However, in the absence of definitive molecular characterization, and specifically, identification of signature glycation conjugates retaining the glucuronyl and carboxyl residues, it cannot be assumed any of these adducts is derived uniquely or even fractionally from AG metabolites. We have therefore undertaken targeted mass spectrometric analyses of human serum albumin (HSA) isolated from diclofenac patients to characterize drug-: derived structures and, thereby, for the first time, have deconstructed conclusively the pathways of adduct formation from a drug AG and its isomeric rearrangement products in vivo. These analyses were informed by a thorough understanding of the reactions of HSA with diclofenac AG in vitro. HSA from six patients without drug-: related hypersensitivities had either a single drug-: derived adduct or one of five combinations of 2-8 adducts from among seven diclofenac N-acylations and three AG glycations on seven of the protein's 59 lysines. Only acylations were found in every patient. We present evidence that HSA modifications by diclofenac in vivo are complicated and variable, that at least a fraction of these modifications are derived from the drug's AG metabolite, and that albumin adduction is not inevitably a causation of hypersensitivity to carboxylate drugs or a coincidental association.
Collapse
Affiliation(s)
- Thomas G Hammond
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Xiaoli Meng
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Rosalind E Jenkins
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - James L Maggs
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Anahi Santoyo Castelazo
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Sophie L Regan
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Stuart N L Bennett
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Caroline J Earnshaw
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Guruprasad P Aithal
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Ira Pande
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - J Gerry Kenna
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Andrew V Stachulski
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - B Kevin Park
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| | - Dominic P Williams
- Medical Research Council Centre for Drug Safety Science, Institute of Translational Medicine, (T.G.H., X.M., R.E.J., J.L.M., A.S.C., S.L.R., C.J.E., B.K.P., D.P.W.) and Department of Chemistry (A.V.S.), University of Liverpool, Liverpool, United Kingdom; Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases-Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham (G.P.A.) and Department of Rheumatology, Nottingham University Hospitals NHS Trust (I.P.), Nottingham, United Kingdom; and AstraZeneca U.K. Ltd (S.N.L.B.) and Safety Assessment, AstraZeneca U.K. Ltd (J.G.K.), Alderley Park, Macclesfield, Cheshire, United Kingdom
| |
Collapse
|
15
|
Monrad RN, Errey JC, Barry CS, Iqbal M, Meng X, Iddon L, Perrie JA, Harding JR, Wilson ID, Stachulski AV, Davis BG. Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein. Chem Sci 2014. [DOI: 10.1039/c4sc01329h] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Blood-protein transacylation/glycosylation reactivity of glucuronides may distinguish beneficial (e.g., ibuprofen) and toxic (e.g., ibufenac) drugs.
Collapse
Affiliation(s)
- Rune Nygaard Monrad
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - James C. Errey
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - Conor S. Barry
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| | - Mazhar Iqbal
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Xiaoli Meng
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Lisa Iddon
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Jennifer A. Perrie
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - John R. Harding
- Drug Metabolism and Pharmacokinetics
- Astra Zeneca
- Cheshire SK10 4TG, UK
| | - Ian D. Wilson
- Drug Metabolism and Pharmacokinetics
- Astra Zeneca
- Cheshire SK10 4TG, UK
| | - Andrew V. Stachulski
- The Robert Robinson Laboratories
- Department of Chemistry
- University of Liverpool
- Liverpool, UK
| | - Benjamin G. Davis
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford, UK
| |
Collapse
|
16
|
Killick DA, Bushby N. A modern approach to the synthesis of 2-(4-chlorophenyl)[2- 14C]thiazol-4-ylacetic acid ([ 14C] fenclozic acid) and its acyl glucuronide metabolite. J Labelled Comp Radiopharm 2013; 56:17-21. [DOI: 10.1002/jlcr.2985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2012] [Revised: 08/23/2012] [Accepted: 10/17/2012] [Indexed: 11/11/2022]
Affiliation(s)
- David A. Killick
- DMPK IM; AstraZeneca UK Ltd; Mereside, Alderley Park; Macclesfield; Cheshire; SK10 4TG; UK
| | - Nick Bushby
- DMPK IM; AstraZeneca UK Ltd; Mereside, Alderley Park; Macclesfield; Cheshire; SK10 4TG; UK
| |
Collapse
|
17
|
Stachulski AV, Meng X. Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides. Nat Prod Rep 2013; 30:806-48. [DOI: 10.1039/c3np70003h] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
18
|
In silico prediction of acyl glucuronide reactivity. J Comput Aided Mol Des 2011; 25:997-1005. [DOI: 10.1007/s10822-011-9479-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Accepted: 10/12/2011] [Indexed: 11/26/2022]
|
19
|
Latli B, Hrapchak M, Seetharama R, Krishnamurthy D, Senanayake CH. Chemical synthesis of allyl-[13C6]-glucuronate. J Labelled Comp Radiopharm 2011. [DOI: 10.1002/jlcr.1875] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
20
|
Iddon L, Richards SE, Johnson CH, Harding JR, Wilson ID, Nicholson JK, Lindon JC, Stachulski AV. Synthesis of a series of phenylacetic acid 1-β-O-acyl glucosides and comparison of their acyl migration and hydrolysis kinetics with the corresponding acyl glucuronides. Org Biomol Chem 2011; 9:926-34. [DOI: 10.1039/c0ob00820f] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
21
|
Imanishi M, Hattori K. Discovery of Novel Selective Human .BETA.3 Adrenergic Receptor Agonists as Potential Overactive Bladder (OAB) Therapies. J SYN ORG CHEM JPN 2011. [DOI: 10.5059/yukigoseikyokaishi.69.1402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
22
|
Karlsson ES, Johnson CH, Sarda S, Iddon L, Iqbal M, Meng X, Harding JR, Stachulski AV, Nicholson JK, Wilson ID, Lindon JC. High-performance liquid chromatography/mass spectrometric and proton nuclear magnetic resonance spectroscopic studies of the transacylation and hydrolysis of the acyl glucuronides of a series of phenylacetic acids in buffer and human plasma. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:3043-3051. [PMID: 20872637 DOI: 10.1002/rcm.4740] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The use of high-performance liquid chromatography/mass spectrometry (HPLC/MS) and proton nuclear magnetic resonance ((1)H NMR) spectroscopy for the kinetic analysis of acyl glucuronide (AG) isomerisation and hydrolysis of the 1-β-O-acyl glucuronides (1-β-O-AG) of phenylacetic acid, (R)- and (S)-α-methylphenylacetic acid and α,α-dimethylphenylacetic acid is described and compared. Each AG was incubated in both aqueous buffer, at pH 7.4, and control human plasma at 37°C. Aliquots of these incubations, taken throughout the reaction time-course, were analysed by HPLC/MS and (1)H NMR spectroscopy. In buffer, transacylation reactions predominated, with relatively little hydrolysis to the free aglycone observed. In human plasma incubations the calculated rates of reaction were much faster than for buffer and, in contrast to the observations in buffer, hydrolysis to the free aglycone was a significant contributor to the overall reaction.A diagnostic analytical methodology based on differential mass spectrometric fragmentation of 1-β-O-AGs compared to the 2-, 3- and 4-positional isomers, which enables selective determination of the former, was confirmed and applied. These findings show that HPLC/MS offers a viable alternative to the more commonly used NMR spectroscopic approach for the determination of the transacylation and hydrolysis reactions of these AGs, with the major advantage of having the capability to do so in a complex biological matrix such as plasma.
Collapse
Affiliation(s)
- Elin S Karlsson
- Department of Clinical Pharmacology, Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire SK10 4TG, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Johnson CH, Karlsson E, Sarda S, Iddon L, Iqbal M, Meng X, Harding JR, Stachulski AV, Nicholson JK, Wilson ID, Lindon JC. Integrated HPLC-MS and (1)H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides. Xenobiotica 2010; 40:9-23. [PMID: 19919325 DOI: 10.3109/00498250903348720] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Acyl glucuronides (AGs) are common, chemically reactive metabolites of acidic xenobiotics. Concerns about the potential of this class of conjugate to cause toxicity in man require efficient methods for the determination of reactivity, and this is commonly done by measuring transacylation kinetics. High-performance liquid chromatography-mass spectrometry (HPLC-MS) and nuclear magnetic resonance (NMR) spectroscopy were applied to the kinetic analysis of AG isomerization and hydrolysis for the 1-beta-O-AGs of ibufenac, (R)- and (S)-ibuprofen, and an alpha,alpha-dimethylated ibuprofen analogue. Each AG was incubated in either aqueous buffer at pH 7.4 or human plasma at 37 degrees C. Aliquots of these samples, taken throughout the reaction time course, were analysed by HPLC-MS and (1)H-NMR spectroscopy and the results compared. For identification of the AGs incubated in pH 7.4 buffer and for analysis of kinetic rates, (1)H-NMR spectroscopy generally gave the most complete set of data, but for human plasma the use of (1)H-NMR spectroscopy was impractical and HPLC-MS was more suitable. HPLC-MS was more sensitive than (1)H-NMR spectroscopy, but the lack of suitable stable-isotope labelled internal standards, together with differences in response between glucuronides and aglycones, made quantification problematic. Using HPLC-MS a specific 1-beta-O-AG-related ion at m/z 193 (the glucuronate fragment) was noted enabling selective determination of these isomers. In buffer, transacylation reactions predominated, with relatively little hydrolysis to the free aglycone observed. In human plasma incubations the observed rates of reaction were much faster than for buffer, and hydrolysis to the free aglycone was the major route. These results illustrate the strengths and weaknesses of each analytical approach for this class of analyte.
Collapse
Affiliation(s)
- C H Johnson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Codée JDC, Christina AE, Walvoort MTC, Overkleeft HS, van der Marel GA. Uronic acids in oligosaccharide and glycoconjugate synthesis. Top Curr Chem (Cham) 2010; 301:253-89. [PMID: 21222193 DOI: 10.1007/128_2010_111] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
This chapter describes the assembly of uronic acid containing oligosaccharides and glycoconjugates. Two strategies are available to access these target molecules, namely a pre-glycosylation oxidation approach, in which uronic acid building blocks are used, and a post-glycosylation oxidation strategy, which employs an oxidation step after the assembly of the oligosaccharide chain. Because uronic acid building blocks are generally considered to be less reactive than their non-oxidized counterparts, the latter approach has found most application in carbohydrate synthesis. With the aid of selected examples of recent syntheses of biologically relevant oligosaccharides and glycoconjugates, the reactivity of different uronic acid building blocks is evaluated. From these examples it is apparent that the generally assumed low reactivity of uronic acids does not a priori rule out an efficient assembly of these target compounds. Besides influencing the reactivity of a given pyranoside, the C-5 carboxylic acid function can also have a profound effect on the stereochemical course of a glycosylation reaction, which can be exploited in the stereoselective formation of glycosidic bonds.
Collapse
Affiliation(s)
- Jeroen D C Codée
- Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
| | | | | | | | | |
Collapse
|
25
|
Iddon L, Bragg RA, Harding JR, Stachulski AV. A convenient new synthesis of quaternary ammonium glucuronides of drug molecules. Tetrahedron 2010. [DOI: 10.1016/j.tet.2009.10.113] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2009.06.060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
27
|
Gauthier C, Legault J, Rondeau S, Pichette A. Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2008.12.043] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
28
|
Berry NG, Iddon L, Iqbal M, Meng X, Jayapal P, Johnson CH, Nicholson JK, Lindon JC, Harding JR, Wilson ID, Stachulski AV. Synthesis, transacylation kinetics and computational chemistry of a set of arylacetic acid 1β-O-acyl glucuronides. Org Biomol Chem 2009; 7:2525-33. [DOI: 10.1039/b822777b] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
29
|
Baba A, Yoshioka T. Structure−Activity Relationships for Degradation Reaction of 1-β-O-Acyl Glucuronides: Kinetic Description and Prediction of Intrinsic Electrophilic Reactivity under Physiological Conditions. Chem Res Toxicol 2008; 22:158-72. [DOI: 10.1021/tx800292m] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Akiko Baba
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, 047-0264, Hokkaido, Japan
| | - Tadao Yoshioka
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, 047-0264, Hokkaido, Japan
| |
Collapse
|
30
|
Johnson CH, Athersuch TJ, Wilson ID, Iddon L, Meng X, Stachulski AV, Lindon JC, Nicholson JK. Kinetic andJ-Resolved Statistical Total Correlation NMR Spectroscopy Approaches to Structural Information Recovery in Complex Reacting Mixtures: Application to Acyl Glucuronide Intramolecular Transacylation Reactions. Anal Chem 2008; 80:4886-95. [DOI: 10.1021/ac702614t] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Caroline H. Johnson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Toby J. Athersuch
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Ian D. Wilson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Lisa Iddon
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Xiaoli Meng
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Andrew V. Stachulski
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - John C. Lindon
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Jeremy K. Nicholson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| |
Collapse
|
31
|
Baba A, Yoshioka T. An Improved Chemo-Enzymatic Synthesis of 1-β-O-Acyl Glucuronides: Highly Chemoselective Enzymatic Removal of Protecting Groups from Corresponding Methyl Acetyl Derivatives. J Org Chem 2007; 72:9541-9. [DOI: 10.1021/jo701547b] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- Akiko Baba
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, 047-0264, Hokkaido, Japan
| | - Tadao Yoshioka
- Hokkaido Pharmaceutical University School of Pharmacy, 7-1 Katsuraoka-cho, Otaru, 047-0264, Hokkaido, Japan
| |
Collapse
|
32
|
Meng X, Maggs JL, Pryde DC, Planken S, Jenkins RE, Peakman TM, Beaumont K, Kohl C, Park BK, Stachulski AV. Cyclization of the acyl glucuronide metabolite of a neutral endopeptidase inhibitor to an electrophilic glutarimide: synthesis, reactivity, and mechanistic analysis. J Med Chem 2007; 50:6165-76. [PMID: 17985860 DOI: 10.1021/jm0706766] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The neutral endopeptidase inhibitor (2R)-2-[(1-{[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl}cyclopentyl)methyl]pentanoic acid 2 is metabolized to acyl glucuronide 3. Unprecedentedly, at pH 7.4, 3 does not undergo the O-acyl migration characteristic of acyl glucuronides but rapid, eliminative cyclization (t1/2 at 37 degrees C, 10.2 min) to glutarimide 4. Glucuronide 3 was synthesized efficiently via acylation of benzylglucuronate with N-benzyloxymethyl-protected 2. Glucuronide and imide reacted rapidly in aqueous solution, pH 7.4, with amino acids and glutathione to form stable amides and unstable thioesters. Imide 4 acylated eight lysine Nepsilon-amino groups of human serum albumin. Rapid cyclization of 3 was attributed to attack on the ester linkage by an unusually nucleophilic glutaramide NH (pKa in 2 = 9.76). N-propyl 3 was refractory to acyl migration and cyclization. This suggested a synthetic strategy for preparing analogues of 2 that form chemically stable acyl glucuronides.
Collapse
Affiliation(s)
- Xiaoli Meng
- The Robert Robinson Laboratories, Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Johnson CH, Wilson ID, Harding JR, Stachulski AV, Iddon L, Nicholson JK, Lindon JC. NMR Spectroscopic Studies on the in Vitro Acyl Glucuronide Migration Kinetics of Ibuprofen ((±)-(R,S)-2-(4-Isobutylphenyl) Propanoic Acid), Its Metabolites, and Analogues. Anal Chem 2007; 79:8720-7. [DOI: 10.1021/ac071368i] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Caroline H. Johnson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Ian D. Wilson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - John R. Harding
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Andrew V. Stachulski
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Lisa Iddon
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - Jeremy K. Nicholson
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| | - John C. Lindon
- Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London SW7 2AZ, U.K., Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Macclesfield, Cheshire SK 10 4TG, U.K., and Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, U.K
| |
Collapse
|